Two research blends, three shared components, one difference. This comparison is written from the composition of each preparation and the way each is documented, not from claims about what either does.
Both blends are supplied as a single lyophilised powder in a sealed glass vial. GLOW contains three peptides; KLOW contains the same three and adds a fourth. The labeled amounts of the shared components are identical.
| Component | Class | GLOW Blend 70mg | KLOW Blend 80mg |
|---|---|---|---|
| Body Protection Compound 157 | 15-residue synthetic peptide derived from a gastric-juice protein | 10 mg | 10 mg |
| TB | 43-residue actin-binding peptide of the thymosin family | 10 mg | 10 mg |
| GHK | Copper-binding tripeptide, supplied as its copper complex | 50 mg | 50 mg |
| KPV | Melanocortin-derived tripeptide (the C-terminal three residues of α-MSH) | — | 10 mg |
| Total labeled content | 70 mg | 80 mg |
Component identifiers (molecular formula, molecular weight, PubChem record and, where PubChem lists one, the CAS number) are shown on each product page: GLOW Blend 70mg and KLOW Blend 80mg.
KPV is the shortest component in either blend: three residues, lysine-proline-valine, corresponding to the C-terminal end of the melanocortin peptide α-MSH. In the laboratory literature it is studied for its interaction with melanocortin receptors and, separately, for its uptake by the intestinal peptide transporter PepT1 in cell and rodent models (references below). Adding it to the GLOW set brings a melanocortin-pathway component into a preparation whose other three components are studied in cytoprotection, actin dynamics and copper-dependent gene expression.
That is the whole of the difference: one additional peptide with its own literature. Nothing about the other three components changes.
A blend is a research convenience: four peptides that a study design calls for together, weighed into one vial. It does not turn four literatures into one. When results from a blend are interpreted, the attribution question, which component did what, remains open unless the design isolates it.
A blend's certificate of analysis has to answer a question a single-compound certificate does not: not only how pure the material is, but how much of each component is present. Our certificates for both blends report, for the lot shipping, the measured content of each component against the amount labeled, the purity of the blend as tested, the net content of the vial, and a separate endotoxin result. The current lot, its figures and both PDFs are shown on each product page and on the COA page.
| Documentation | GLOW Blend 70mg | KLOW Blend 80mg |
|---|---|---|
| Per-component measured content | Three components | Four components |
| Purity of the blend as tested | Reported per lot | Reported per lot |
| Net content vs labeled | Reported per lot | Reported per lot |
| Endotoxin | Separate endotoxin report (most lots; method not stated) | Separate endotoxin report (most lots; method not stated) |
| Lot traceability | Lot number on vial and certificate | Lot number on vial and certificate |
The choice follows the study design rather than the blend. If the melanocortin-derived component is part of the question, KLOW is the preparation that contains it. If it is not, GLOW isolates the three shared components and removes one variable. Laboratories that run both preparations side by side are, in effect, running a four-versus-three comparison in which KPV is the only difference, which is the cleanest way to attribute any observed difference to it.
GLOW is a three-component research blend of Body Protection Compound 157, TB and GHK. KLOW contains the same three components in the same labeled amounts and adds a fourth, KPV, a melanocortin-derived tripeptide. Everything else about the two preparations, including how each is documented on its certificate of analysis, is the same.
A single purity figure for a blend says only how much of the vial is peptide, not which peptides or in what amounts. Our certificates report the measured content of each component against the amount labeled, so the composition can be checked, not assumed.
That depends on the question the experiment asks. If the melanocortin-derived component is part of the model, KLOW is the preparation that contains it; if it is not, GLOW isolates the three shared components. Both are sold for laboratory research only.
Yes. Body Protection Compound 157 at 10 mg, TB at 10 mg and GHK at 50 mg are labeled identically in GLOW and KLOW, and the same component identifiers apply to both.
Explore our catalog of research-grade peptides with certificates of analysis.
KLOW Blend 80mg GLOW Blend 70mgDisclaimer: All compounds referenced in this article are intended for laboratory research use only. They are not approved for human or veterinary use by the FDA or any regulatory agency. This article describes composition and documentation; it makes no claims about any compound's effects in people, and it does not describe or recommend any use, administration or dosing of any compound.